COMUNICACIÓN ORAL | 03 noviembre 2023, viernes | Hora: 17:30
AUTORES
Díaz Manera, Jordi 1; null, Drago 2; null, Barry J. 3; null, Kristl G. 4; null, Priya 5; null, Pascal 6; null, Tahseen 7; null, Mark 8; null, Antonio 9; null, Jeff 10; null, Mitchell 11; null, Hai 12; null, Sheela 13; null, Yasmine 14; null, Benedikt 15; Alonso ., Jorge 16
CENTROS
1. Servicio: John Walton Muscular Dystrophy Research Centre. Newcastle University; 2. Servicio: PARC Research Clinic. Royal Adelaide Hospital; 3. Servicio: Powell Gene Therapy Center. University of Florida; 4. Servicio: Department of Neurology. University Hospitals Leuven; 5. Servicio: Duke University Medical Center. Duke University; 6. Servicio: Nord-Est/Ile-de-France Neuromuscular Reference Center, Neurology Department. Raymond-Poincaré Hospital; 7. Servicio: Department of Neurology. University of California; 8. Servicio: Neurology. Salford Royal NHS Foundation Trust; 9. Servicio: Neurology and Neuromuscular Disorders Unit, Department of Clinical and Experimental Medicine. Università di Messina; 10. Servicio: Chief Development Officer. Amicus Therapeutics, Inc.; 11. Servicio: Chief Medical Officer. Amicus Therapeutics, Inc.; 12. Servicio: Head of Biostatistics and Programming. Amicus Therapeutics, Inc.; 13. Servicio: Vice President, Program Management. Amicus Therapeutics, Inc.; 14. Servicio: Vice President, Clinical Research. Amicus Therapeutics, Inc.; 15. Friedrich-Baur-Institut, Neurologische Klinik. Ludwig-Maximilians-Universität München; 16. Unidad Enf. Neuromusculares, Servicio Neurología. En nombre del Grupo de estudio ATB200-07. Complejo Hospital Universitario Nuestra Sra. de Candelaria
Leer más…